ArticleScientific reports2025
Anti-cancer activity of propolis extracts from stingless bees of Brunei Darussalam.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Propolis from stingless bees is a natural resinous substance with diverse therapeutic properties, including anti-cancer activity. Despite increasing global interest, little is known about the bioactive potential of propolis from Southeast Asian stingless bees, particularly those native to Brunei Darussalam. Therefore, we investigated propolis extracts from five stingless bee species in Brunei and elucidated the underlying molecular mechanisms using transcriptomic and metabolomic profiling. Propolis extracts from Heterotrigona itama, Tetragonula melanoleuca, Tetrigona binghami, Geniotrigona thoracica, and Lepidotrigona canifrons were tested against lymphoma (U2932, HT, OCI-LY3), lung (H1975) and bladder (EJ) cancer cell lines. RNAseq and pathway enrichment analysis were performed to investigate the molecular mechanisms influenced by ethanol extracts from the three stingless bee species, H. itama, T. binghami, and T. melanoleuca on representative cell lines. Gas chromatography/mass spectrometer (GC-MS)-based metabolomics was performed for metabolite profiling of ethanol and ethyl acetate propolis extracts. Ethanol extracts elicited greater anticancer activity in general, as compared to ethyl acetate extracts. Ethanol propolis extracts from T. melanoleuca and H. itama were the most potent amongst the five stingless bee species, particularly on the lymphoma cell lines. Transcriptomic pathways involved in cell cycle progression, including E2F Targets and G2M Checkpoint, were downregulated in the EJ and H1975 cell lines, suggesting that the extracts may induce cell cycle arrest, particularly in adherent cells. MTORC1 signaling were downregulated across multiple cell lines. Interestingly, upregulation of several inflammation-related pathways, including TNFα signaling via NF-κB, Interferon Alpha Response, Interferon Gamma Response, and Inflammatory Response was observed. GC-MS analysis identified six major classes of compounds, including polyketides, phenolic acids and terpenoids, which were enriched in ethanol compared with ethyl acetate extracts. Propolis extracts from Brunei stingless bees demonstrate anti-cancer properties associated with pro-inflammatory and anti-oncogenic signalling activity. These findings support further investigation of their bioactive constituents as anti-cancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.